van der Graaf WTA - Search Results

1

Systemic Treatment for Adults with Synovial Sarcoma.

Desar IME, Fleuren EDG, van der Graaf WTA. Desar IME, et al. Among authors: van der graaf wta. Curr Treat Options Oncol. 2018 Mar 7;19(2):13. doi: 10.1007/s11864-018-0525-1. Curr Treat Options Oncol. 2018. PMID: 29516254 Free PMC article. Review.

2

Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.

Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Desar IM, et al. Cancer Treat Rev. 2009 Jun;35(4):309-21. doi: 10.1016/j.ctrv.2008.12.001. Epub 2009 Jan 10. Cancer Treat Rev. 2009. PMID: 19136215 Review.

3

Pharmacokinetics of sunitinib in an obese patient with a GIST.

Desar IM, Burger DM, Van Hoesel QG, Beijnen JH, Van Herpen CM, Van der Graaf WT. Desar IM, et al. Ann Oncol. 2009 Mar;20(3):599-600. doi: 10.1093/annonc/mdn779. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153120 Free article. No abstract available.

4

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM. Desar IM, et al. Acta Oncol. 2009;48(6):927-31. doi: 10.1080/02841860902974167. Acta Oncol. 2009. PMID: 19452305 No abstract available.

5

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.

Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, Van Der Graaf WT, Van Rossum MM, Van Herpen CM. Desar IM, et al. Acta Oncol. 2010;49(1):110-3. doi: 10.3109/02841860903104152. Acta Oncol. 2010. PMID: 19634052 No abstract available.

6

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

Desar IM, Jacobs JH, Hulsbergen-vandeKaa CA, Oyen WJ, Mulders PF, van der Graaf WT, Adema GJ, van Herpen CM, de Vries IJ. Desar IM, et al. Int J Cancer. 2011 Jul 15;129(2):507-12. doi: 10.1002/ijc.25674. Epub 2010 Nov 12. Int J Cancer. 2011. PMID: 20839259 Free article.

7

111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Desar IM, Stillebroer AB, Oosterwijk E, Leenders WP, van Herpen CM, van der Graaf WT, Boerman OC, Mulders PF, Oyen WJ. Desar IM, et al. J Nucl Med. 2010 Nov;51(11):1707-15. doi: 10.2967/jnumed.110.078030. Epub 2010 Oct 18. J Nucl Med. 2010. PMID: 20956472 Free article.

8

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Desar IM, Timmer-Bonte JN, Burger DM, van der Graaf WT, van Herpen CM. Desar IM, et al. Br J Cancer. 2010 Nov 23;103(11):1637-43. doi: 10.1038/sj.bjc.6605777. Epub 2010 Nov 2. Br J Cancer. 2010. PMID: 21045832 Free PMC article. Clinical Trial.

9

A new, simple and objective prognostic score for phase I cancer patients.

Füssenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM. Füssenich LM, et al. Eur J Cancer. 2011 May;47(8):1152-60. doi: 10.1016/j.ejca.2010.12.028. Epub 2011 Feb 25. Eur J Cancer. 2011. PMID: 21354785

10

Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway.

Desar IM, Thijs AM, Mulder SF, Tack CJ, van Herpen CM, van der Graaf WT. Desar IM, et al. Anticancer Drugs. 2012 Feb;23(2):149-54. doi: 10.1097/CAD.0b013e32834b3fae. Anticancer Drugs. 2012. PMID: 21876435 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

619 results

Search Page